Glomerulonephritis (GN) is an inflammatory disease of the glomeruli—the kidney's microscopic filtration units—triggered by immune complex deposition (Type III hypersensitivity), autoantibodies attacking glomerular structures (Type II hypersensitivity), or direct T cell-mediated damage. The inflammation disrupts the delicate filtration barrier, leading to proteinuria, hematuria, and progressive loss of kidney function. GN represents a common pathway through which systemic autoimmune diseases, infections, and immune dysregulation manifest as kidney damage.
Imagine the glomerulus as a high-tech water purification plant with thousands of ultra-fine mesh filters (the glomerular basement membrane). Normally, this plant filters blood at incredible speed—125 mL/minute—allowing clean water and waste through while keeping proteins and cells inside the circulation. Now imagine immune complexes as clumps of sticky debris (antigen-antibody clusters) that get lodged in the mesh like hairballs in a drain. Once stuck, they trigger an alarm system (complement activation) that calls in demolition workers (neutrophils and macrophages). These workers arrive with powerful tools—proteases, reactive oxygen species—designed to break up the debris, but they're working in a confined space. Their chemical weapons damage the delicate mesh itself, creating holes that now let proteins leak through (proteinuria) and allow red blood cells to escape (hematuria). In some cases, instead of debris getting stuck, saboteurs (autoantibodies) directly attack the mesh structure itself, cutting the wires. Either way, the filtration plant becomes progressively less efficient, and if the damage continues, the entire facility eventually shuts down (chronic kidney disease).
Glomerulonephritis develops through three primary pathogenic mechanisms, each with distinct molecular cascades:
Formation and Deposition:
Circulating immune complexes (antigen + IgG/IgM antibodies) → preferential deposition in glomerular capillaries (due to fenestrated endothelium, high blood flow, and mesangial trapping) → complexes lodge in subendothelial, subepithelial, or mesangial spaces
Complement Activation:
Deposited immune complexes → C1q binding to Fc regions of antibodies → activation of classical complement pathway → C3 convertase formation → C3a and C5a generation (anaphylatoxins) → neutrophil chemotaxis → C5b-9 (membrane attack complex) assembly → direct podocyte and endothelial injury
Cellular Infiltration:
C5a → neutrophil recruitment via C5aR1 receptors → neutrophil degranulation releasing elastase, myeloperoxidase, matrix metalloproteinases (MMPs) → basement membrane degradation → Macrophage recruitment via CCL2 (MCP-1) → M1 polarization → TNF-α, IL-1β, IL-6 secretion → amplification of local inflammation
SLE-Specific Pathway:
Anti-dsDNA antibodies + nucleosomes → immune complex formation → preferential glomerular deposition (nucleosomes bind directly to glomerular basement membrane via heparan sulfate) → type III hypersensitivity cascade → additionally, direct anti-DNA antibody binding to α-actinin in podocytes → podocyte cytoskeletal disruption
Anti-glomerular basement membrane antibodies (targeting NC1 domain of α3 chain of type IV collagen) → direct antibody binding to basement membrane → complement-independent and complement-dependent cytotoxicity → Fc receptor engagement on macrophages and NK cells → ADCC (antibody-dependent cellular cytotoxicity) → basement membrane destruction
Autoantibodies against neutrophil cytoplasmic antigens (PR3 or MPO) → neutrophil priming by inflammatory cytokines → ANCA binding to surface-expressed PR3/MPO → neutrophil activation → respiratory burst → reactive oxygen species production → degranulation → glomerular capillary necrosis (necrotizing glomerulonephritis) → crescent formation from proliferating parietal epithelial cells
Resolution Failure:
In GN, the normal resolution mechanisms fail catastrophically. SPMs (resolvins, protectins, maresins) are insufficient to counter overwhelming inflammation → incomplete efferocytosis of apoptotic neutrophils → persistent M1 macrophage polarization → failure to switch from COX-2 to 15-LOX → chronic inflammatory state → progressive fibrosis via TGF-β signaling → myofibroblast activation → collagen I and III deposition → glomerulosclerosis
Glomerulonephritis represents a critical intersection of systemic immune dysregulation and end-organ damage, making it a sentinel condition in cPNI practice. Recognition requires integration across multiple metamodels:
Metamodel 0 (Energy Distribution): The kidney is metabolically expensive tissue (7% of cardiac output for 0.5% of body weight). Inflammatory damage triggers a metabolic crisis—damaged glomeruli require increased ATP for repair while simultaneously losing filtration capacity, creating positive feedback toward kidney failure. The "selfish kidney" may sacrifice other organs through hypertension and metabolic waste accumulation.
Metamodel 2 (Immune Dysregulation): GN is often the clinical manifestation of failed immune tolerance and defective resolution. In SLE nephritis (50-60% of SLE patients), anti-dsDNA antibody levels >200 IU/mL correlate with nephritis risk. The condition exemplifies how chronic low-grade inflammation (metaflammation) from gut dysbiosis, oral pathogens (particularly Porphyromonas gingivalis), or persistent viral infections can provide the antigen load for immune complex formation.
Clinical Thresholds:
cPNI Intervention Framework:
Address Immune Complex Formation: Reduce antigenic burden through gut barrier repair (zinc carnosine 75 mg BID, glutamine 5g TID), oral dysbiosis treatment, chronic infection screening (EBV, CMV reactivation)
Promote Resolution: High-dose omega-3 (EPA+DHA 4-6g/day) to shift eicosanoid balance toward SPM production, curcumin (1000 mg BID with piperine) for NF-ÎşB inhibition and resolution promotion
Mitochondrial Support: The damaged kidney is in severe metabolic crisis—support with CoQ10 (200-300 mg/day), alpha-lipoic acid (600 mg/day), and careful protein restriction (0.6-0.8 g/kg/day) to reduce metabolic load while preserving muscle
Complement Modulation: Vitamin D optimization (25-OH-D >40 ng/mL) modulates complement activation, quercetin (500 mg BID) inhibits complement C5
Monitor Evolutionary Mismatch: GN rates are rising alongside autoimmune disease generally—likely reflecting chronic low-grade inflammation from Western diet, sedentary behavior, circadian disruption, and microbiome perturbation
Critical Clinical Context: Conventional immunosuppression (corticosteroids, cyclophosphamide, mycophenolate) may control acute inflammation but fails to address root causes. Many patients develop steroid resistance through glucocorticoid resistance mechanisms (increased GR-β expression, FKBP5 polymorphisms). The cPNI approach recognizes that GN is rarely just a kidney disease—it's a whole-systems metabolic and immune catastrophe requiring multi-level intervention.